Financial Performance - The company's revenue for Q1 2023 was ¥619,002,726.63, representing a decrease of 49.25% compared to the same period last year[4] - The net profit attributable to shareholders was -¥149,816,707.55, a decline of 143.78% year-over-year[4] - The net cash flow from operating activities was -¥451,671,394.87, reflecting a decrease of 493.91% compared to the previous year[4] - The basic earnings per share were -¥0.36, a decrease of 139.13% compared to the same period last year[4] - Total operating revenue for Q1 2023 was ¥619,002,726.63, a decrease of 49.2% compared to ¥1,219,792,640.81 in Q1 2022[27] - Net loss for Q1 2023 was ¥150,045,829.72, compared to a net profit of ¥342,050,181.17 in Q1 2022[28] - Other comprehensive income after tax for Q1 2023 was -¥20,173,635.34, compared to -¥10,493,513.28 in Q1 2022[28] - The company reported a comprehensive loss of ¥170,219,465.06 in Q1 2023, compared to a comprehensive income of ¥331,556,667.89 in Q1 2022[28] Research and Development - Research and development expenses totaled ¥218,799,003.24, an increase of 40.10% year-over-year, accounting for 35.35% of total revenue, up 22.54 percentage points[6] - R&D expenses increased to ¥218,799,003.24 in Q1 2023, up 40.0% from ¥156,167,891.07 in Q1 2022[27] - The company plans to continue investing in technology and product innovation in areas such as gene sequencing instruments and automation systems[10] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,721,111,718.51, a decrease of 4.43% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to approximately ¥10.72 billion, a decrease from ¥11.22 billion as of December 31, 2022[24] - Total liabilities decreased to ¥1,435,574,221.97 in Q1 2023 from ¥1,765,726,951.92 in Q1 2022, a reduction of 18.6%[26] - Total equity decreased to ¥9,285,537,496.54 in Q1 2023 from ¥9,452,593,954.56 in Q1 2022, a decline of 1.8%[26] Cash Flow - The company's cash and cash equivalents decreased to approximately ¥5.92 billion from ¥6.48 billion year-over-year[24] - The net cash outflow from operating activities was ¥451,671,394.87, contrasting with a net inflow of ¥114,664,822.75 in the same period last year[30] - Cash outflows for purchasing goods and services amounted to ¥569,709,074.92, down from ¥639,661,123.15 in Q1 2022, indicating a reduction of about 11%[30] - The company experienced a net cash outflow from investing activities of ¥58,564,670.42, compared to a smaller outflow of ¥13,794,184.28 in Q1 2022[31] - Cash outflows related to financing activities totaled ¥19,558,891.20, which is an increase from ¥11,131,869.97 in the previous year[31] - The net decrease in cash and cash equivalents for the quarter was ¥557,075,740.90, contrasting with an increase of ¥76,774,763.74 in Q1 2022[31] - The ending balance of cash and cash equivalents was ¥5,911,909,785.68, down from ¥2,662,223,101.48 at the end of Q1 2022[31] Market and Product Developments - The decline in revenue was primarily due to a decrease in demand for automation products[9] - The company launched its full range of sequencing products in the U.S. in January 2023, enhancing sequencing capabilities for users across various fields[21] - The newly released DNBSEQ-T20×2 sequencing instrument achieves a single-run throughput of 42Tb (PE100) or 72Tb (PE150), significantly reducing the cost of whole genome sequencing to below $100[22] - The European Patent Office declared Illumina's patent invalid, allowing the company to sell its full range of sequencing instruments in multiple European countries[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,724[11] Employee Compensation - The company reported a significant reduction in employee compensation liabilities, decreasing from approximately ¥277.29 million to ¥145.79 million[25] - Employee compensation payments rose to ¥441,555,569.23, up from ¥289,413,445.54 in Q1 2022, reflecting a significant increase of about 53%[30]

证券代码：688114 证券简称：华大智造 公告编号：2023- 012 关于参加 2022 年度医疗器械集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 4 月 28 日(星期五)上午 9:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （网址： http://roadshow.sseinfo.com/） 会议召开方式：视频和线上文字互动 投资者可于 2023 年 4 月 27 日(星期四)16:00 前通过邮件、电话、传真等形 式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 深圳华大智造科技股份有限公司（以下简称"公司"）将于 2023 年 4 月 25 日发布《2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况、发展理念，公司参与了由上海证券交易所主办的 2022 年 度医疗器械集体业绩说明会，此次活动将采用视频 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥928,958,162.52, representing a year-over-year increase of 4.63%[4]. - The net profit attributable to shareholders for Q3 2022 was ¥1,678,255,089.16, with a year-to-date increase of 339.85% to ¥4,717,830,352.49[4][9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥44,033,703.73, showing a year-to-date decrease of 24.96%[4]. - The basic earnings per share for Q3 2022 was ¥4.39, with a year-to-date increase of 334.32% to ¥4,582.08[5][9]. - The total profit for the period is approximately CNY 2.62 billion, compared to CNY 541.38 million in the previous period, indicating a significant increase[33]. - The net profit attributable to shareholders of the parent company is approximately CNY 2.02 billion, up from CNY 459.69 million year-over-year[35]. - The basic earnings per share (EPS) is CNY 5.39, compared to CNY 1.24 in the previous period, reflecting a substantial growth in profitability[35]. - The company reported a total comprehensive income for the period of approximately CNY 2.12 billion, compared to CNY 444.12 million in the previous period, indicating robust overall performance[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥11,736,266,013.61, reflecting a 97.47% increase compared to the same period last year[5][10]. - The equity attributable to shareholders at the end of Q3 2022 was ¥9,411,389,087.31, an increase of 134.87% year-over-year[5][10]. - The total liabilities increased to CNY 2.28 billion from CNY 1.87 billion, representing a growth of 21.9%[30]. - Current assets rose to CNY 9.83 billion, compared to CNY 4.27 billion in the previous year, marking an increase of 130.5%[23]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥2,072,381,921.40, reflecting a 250.19% increase[5][9]. - Cash inflows from operating activities totaled approximately CNY 5.66 billion, compared to CNY 3.51 billion in the previous year, showing a strong operational performance[36]. - The net cash flow from operating activities is approximately CNY 2.07 billion, a significant increase from CNY 591.79 million in the previous period[37]. - The company reported a net increase in cash and cash equivalents of approximately CNY 5.23 billion, compared to a decrease of CNY 529.98 million in the previous year[39]. - The company has successfully managed its financial activities, with cash inflows from financing activities amounting to approximately CNY 3.35 billion, compared to CNY 30 million in the previous year[37]. Research and Development - Research and development expenses for Q3 2022 totaled ¥193,767,510.81, accounting for 20.86% of operating revenue, which is an increase of 1.37 percentage points[5]. - Research and development expenses for the third quarter of 2022 were CNY 525.32 million, up from CNY 456.54 million in the same quarter of 2021, indicating a growth of 15.0%[32]. - The company plans to continue expanding its market presence and investing in R&D to enhance product offerings and technological advancements[5]. - The company has ongoing investments in new technologies and products, with a focus on expanding its market presence and enhancing R&D capabilities[31]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,587[11]. - Shenzhen BGI Intelligent Manufacturing Co., Ltd. holds 153,001,440 shares, accounting for 37.04% of the total shares[11]. - The top ten shareholders include CPE Investment (Hong Kong) 2018 Limited, holding 26,378,788 shares, which is 6.39% of the total shares[11]. - The company has not disclosed any related party transactions or concerted actions among the top ten shareholders beyond those mentioned[14]. Impairment Losses - The company recognized credit impairment losses of RMB 22,445,113.23 for accounts receivable and RMB 536,470.58 for other receivables during the reporting period[17]. - The total asset impairment losses for the first nine months of 2022 amounted to RMB 59,057,585.15, which will reduce the total profit for the consolidated financial statements[17]. - The company reported a credit impairment loss of RMB 36,076,001.34 for inventory during the reporting period[17]. Strategic Plans - The company plans to jointly bid for land in Yantian District with Shenzhen BGI Gene Technology Co., Ltd. and other related parties[15]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[40]. - The company received a net compensation of $325 million from Illumina, significantly impacting net profit and cash flow[9][10]. - The company received a net compensation of USD 325 million from Illumina as part of a settlement agreement[16]. - The company has canceled the qualifications of 16 incentive objects due to personal reasons, resulting in the cancellation of 228,100 stock options[16].